HLB Group Receives Full 206.9 Billion Won Investment from LMR Partners

HLB Group announced on November 14 that it has received the full investment amount of 145 million dollars (approximately 206.9 billion won) from the UK-based asset management firm LMR Partners.

HLB secured 140 million dollars by issuing the 42nd registered, non-guaranteed, private, non-separable bond with warrants (BW). HLB Life Science also raised 5 million dollars by issuing registered, non-guaranteed overseas exchangeable bonds.

Previously, on November 3, HLB Group signed an investment agreement with LMR Partners, with global financial institution UBS acting as the sole lead manager.

This marks a significant turning point for HLB Group, as it has successfully secured large-scale global capital for the first time since its founding.

The attraction of foreign capital demonstrates that the group’s new drug development capabilities and clinical results have been recognized by the global capital market. It also serves to strengthen trust in the company’s strategic growth moving forward.

Specifically, HLB and HLB Life Science have secured funds to resolve short-term liquidity concerns, reduce financial burdens, and further enhance the stability of their future business operations.

With a stable operational foundation, Elevar is now able to proceed as planned with FDA approval and commercialization preparations for its liver and bile duct cancer treatments. The company is also well-positioned to accelerate the development of subsequent pipeline candidates.

Lim Changyoon, Vice Chairman of Investments at HLB Group, stated, "Securing capital from a global asset management firm is external recognition of HLB’s future potential. As the group’s financial stability has also been strengthened, we will complete our core pipelines as planned and deliver tangible results in the global market, proving our achievements through sales figures and other metrics."

This content was produced with the assistance of AI translation services.